| 736948 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer |
2021-09-01 |
10.1136/jitc-2021-003238 |
DeMaria Peter J, Lee-Wisdom Katherine, Donahue Renee N, Madan Ravi A, Karzai Fatima, Schwab Angie, Palena Claudia, Jochems Caroline, Floudas Charalampos, Strauss Julius, Marté Jennifer L, Redman Jason Mark, Dombi Eva, Widemann Brigitte, Korchin Borys, Adams Tatiana, Pico-Navarro Cesar, Heery Christopher, Schlom Jeffrey, Gulley James L, Bilusic Marijo |
| 736947 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR |
2021-09-01 |
10.1136/jitc-2021-002627 |
Bayless Nicholas L, Bluestone Jeffrey A, Bucktrout Samantha, Butterfield Lisa H, Jaffee Elizabeth M, Koch Christian A, Roep Bart O, Sharpe Arlene H, Murphy William J, Villani Alexandra-Chloé, Walunas Theresa L |
| 736946 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer |
2021-09-01 |
10.1136/jitc-2021-002876 |
Carbone Carmine, Piro Geny, Agostini Antonio, Delfino Pietro, De Sanctis Francesco, Nasca Vincenzo, Spallotta Francesco, Sette Claudio, Martini Maurizio, Ugel Stefano, Corbo Vincenzo, Cappello Paola, Bria Emilio, Scarpa Aldo, Tortora Giampaolo |
| 736945 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity |
2021-09-01 |
10.1136/jitc-2021-002865 |
Hernandez Rosmely, LaPorte Kathryn M, Hsiung Sunnie, Santos Savio Alicia, Malek Thomas R |
| 736944 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations |
2021-09-01 |
10.1136/jitc-2021-002531corr1 |
|
| 736943 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids |
2021-09-01 |
10.1136/jitc-2021-003000corr1 |
|
| 736942 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers |
2021-09-01 |
10.1136/jitc-2021-002336 |
Ying Jieer, Yang Lin, Yin Jiani C, Xia Guojie, Xing Minyan, Chen Xiaoxi, Pang Jiaohui, Wu Yong, Bao Hua, Wu Xue, Shao Yang, Zhu Lingjun, Cheng Xiangdong |
| 736941 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy |
2021-09-01 |
10.1136/jitc-2021-002443orr1 |
|
| 736940 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor |
2021-09-01 |
10.1136/jitc-2020-002127corr1 |
|
| 736939 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer |
2021-09-01 |
10.1136/jitc-2020-001674corr1 |
|
